Eutilex.Co.Ltd (263050) - Total Liabilities
Based on the latest financial reports, Eutilex.Co.Ltd (263050) has total liabilities worth ₩22.09 Billion KRW (≈ $14.97 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eutilex.Co.Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Eutilex.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See 263050 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Eutilex.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Eutilex.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mitie Group PLC
LSE:MTO
|
UK | GBX2.05 Billion |
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
Turkey | TL2.89 Million |
|
Trend Gayrimenkul Yatirim Ortakligi AS
IS:TDGYO
|
Turkey | TL24.93 Million |
|
Conduril - Engenharia S.A
LS:CDU
|
Portugal | €157.89 Million |
|
WITTED MEGACORP OYJ EO 1
F:8OS
|
Germany | €10.25 Million |
|
Nexus Minerals Ltd
AU:NXM
|
Australia | AU$592.70K |
|
Smartiks Yazilim AS
IS:SMART
|
Turkey | TL107.22 Million |
|
Rig Tenders Tbk
JK:RIGS
|
Indonesia | Rp13.37 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Eutilex.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Eutilex.Co.Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eutilex.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eutilex.Co.Ltd (2016–2024)
The table below shows the annual total liabilities of Eutilex.Co.Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩26.57 Billion ≈ $18.01 Million |
+116.66% |
| 2023-12-31 | ₩12.26 Billion ≈ $8.31 Million |
-26.62% |
| 2022-12-31 | ₩16.71 Billion ≈ $11.33 Million |
-63.11% |
| 2021-12-31 | ₩45.31 Billion ≈ $30.70 Million |
-3.64% |
| 2020-12-31 | ₩47.02 Billion ≈ $31.87 Million |
+256.70% |
| 2019-12-31 | ₩13.18 Billion ≈ $8.93 Million |
+74.17% |
| 2018-12-31 | ₩7.57 Billion ≈ $5.13 Million |
+2.88% |
| 2017-12-31 | ₩7.36 Billion ≈ $4.99 Million |
+29.42% |
| 2016-12-31 | ₩5.68 Billion ≈ $3.85 Million |
-- |
About Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more